Four-Year MATCH Trial Data Shows 70% Transplant-Free Survival with Regenerative Macrophage Therapy in Liver Cirrhosis
核心洞察
Four-year follow-up data from the University of Edinburgh's MATCH trial demonstrates that 70% of patients with liver cirrhosis who received regenerative macrophage therapy remained transplant-free, compared to only 40% receiving standard care.
The positive results support Resolution Therapeutics (搜索)' ongoing Phase I/II EMERALD trial of RTX001, an engineered macrophage therapy enhanced with IL-10 and MMP9 (搜索) for patients with end-stage liver disease.
Resolution's engineered approach targets more severe patient populations who have experienced liver decompensation events, with interim EMERALD data expected in the second half of 2026.
Four-year follow-up data from the University of Edinburgh's MATCH trial has demonstrated significant clinical benefits of regenerative macrophage therapy (RMT) in patients with liver cirrhosis, with 70% of treated patients remaining transplant-free compared to just 40% of those receiving standard care. The results, published in Cell Stem Cell, provide crucial validation for Resolution Therapeutics (搜索)' ongoing development of engineered macrophage therapies.
MATCH Trial Delivers Long-Term Efficacy Data
The MATCH trial, led by Professor Stuart Forbes at the University of Edinburgh, tested the first iteration of RMT using patients' own macrophages without laboratory engineering. The four-year follow-up analysis revealed a favorable safety and tolerability profile with no evidence of increased serious adverse events. Patients treated with RMT showed significantly prolonged transplant-free survival, underscoring the potential of regenerative macrophages as a transformative treatment option for hepatic inflammation and fibrosis.
Resolution Advances Engineered Approach
Building on these foundational results, Resolution Therapeutics (搜索) is pioneering engineered RMT through its lead candidate RTX001. The company's approach enhances patients' macrophages with IL-10 and MMP9 (搜索) to deliver superior anti-inflammatory and anti-fibrotic activity compared to non-engineered macrophages. Extensive preclinical testing has demonstrated that engineered RMT delivers a more potent and durable therapeutic effect than non-engineered versions.
"All of us at Resolution Therapeutics (搜索) would like to congratulate Professor Stuart Forbes and his University of Edinburgh team on this important clinical milestone," said Dr. Clifford Brass, Chief Medical Officer of Resolution Therapeutics. "Our work at Resolution would not have been possible without their foundational research. The MATCH four-year data reinforce the scientific rationale for Regenerative Macrophage Therapies to address inflammation and fibrosis in the liver, targeting a clear and significant unmet medical need."
EMERALD Trial Targets Severe Patient Population
Resolution's Phase I/II EMERALD clinical trial is evaluating RTX001 in patients with end-stage liver disease who have a history of decompensated liver cirrhosis. The engineered approach makes the therapy suitable for treating more severe patient populations, including those who have experienced liver decompensation events such as gastrointestinal bleeding, liver-related confusion, or abdominal fluid buildup with or without infection.
The EMERALD trial is being conducted across leading hospitals in the UK and Spain, with interim data expected in the second half of 2026. This represents a significant advancement from the MATCH trial's non-engineered approach to Resolution's enhanced therapeutic platform.
Expanding Pipeline Beyond Liver Disease
Beyond RTX001, Resolution is developing RMTs for additional inflammatory and fibrotic indications, including graft-versus-host disease (GvHD) and lung fibrosis. These programs are currently in preclinical evaluation, demonstrating the potential broad applicability of the company's regenerative macrophage platform.
Resolution Therapeutics (搜索), a spinout from Professor Forbes's lab at the University of Edinburgh, leverages its proprietary platform to develop macrophages with pro-regenerative properties. The company's initial focus on RTX001 represents a first-in-class potential supported by preclinical data demonstrating anti-fibrotic and anti-inflammatory advantages relative to non-engineered macrophages.